Arch Biopartners doses first subject in trial of acute kidney injury treatment
The multicentre, placebo-controlled trial aims to recruit 240 participants in total.
Drug Development
Disc Medicine secures $200m financing to support trials
OncoResponse reports data from Phase I solid tumour treatment trial
Adapting diabetes clinical trials to embrace underrepresented communities
Genelux doses first subject in Phase II trial of NSCLC treatment
Gilead and MSD to advance once-weekly HIV treatment to Phase III
Galderma reports data from Phase III trial of anti-ageing product RelabotulinumtoxinA
Find Therapeutics dosing subjects in study of FTX-101 for chronic optic neuropathy
